Top Markets
#1 Black Phoenix Black Phoenix +173.62%
#2 Islamic Coin Islamic Coin +158.26%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.42%
#5 DOVU DOVU +18.81%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.03%
#7 MarsCoin MarsCoin +9.43%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +8.87%
#9 Pons Pons +8.77%
#10 stake.link stake.link +8.21%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Biostax Corp. Biostax Corp.

Biostax Corp.

BTAX
Rank in Stocks #41904
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition,... Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$7.87K
Change (1 day)
0.00%
Change (1 year)
-50.00%
Country
US
Trade Biostax Corp. (BTAX)

Category

Healthcare
Revenue for Biostax Corp. (BTAX)
Revenue in Aug 2026 TTM: 0
According to Biostax Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Biostax Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR